High-dose melphalan (HDM) is an essential component in the treatment of patients with multiple myeloma (MM). Few data are available regarding genetic polymorphisms associated with patient outcome or toxicity in this setting. To identify such polymorphisms, we performed a retrospective analysis, genotyping single nucleotide polymorphisms (SNPs) with the arrayed primer extension (APEX) technology in 169 patients having received HDM for MM. We analyzed 209 SNPs in 95 genes involved in drug metabolism, DNA repair, cell cycle and apoptosis. SNPs in ABCB1, CYP3A4 and TP53BP2 were associated with response to VAD induction therapy (Po0.01). SNPs in ALDH2, GSTT2 and BRCA1 were associated with response to HDM (Po0.01). Polymorphisms in CYP1A1, RAD51 and PARP were associated with disease progression whereas polymorphisms in ALDH2 and CYP1A1 were correlated with OS. Polymorphisms in BRCA1, CDKN1A and XRCC1 were associated with the occurrence of severe mucositis after HDM. These results suggest that SNPs of genes involved in drug metabolism or DNA repair could be used to distinguish MM patient subgroups with different toxicity/efficacy profiles.
Introduction
High-dose chemotherapy treatment with SCT has constituted one of the major breakthroughs in the treatment of multiple myeloma (MM) in the past decades.
1 Randomized trials have shown that a course of high-dose melphalan (HDM) (140 or 200 mg/m 2 ) achieves a complete response in approximately 40% of patients, and that a second course enhances the quality of response in patients with suboptimal response after a first course of high-dose therapy. 2 In spite of recent therapeutic advances such as bortezomib or the immunomodulatory drugs, HDM remains a central component in the treatment of patients under the age of 65.
Although melphalan has been available for half a century and its metabolism and mechanisms of action are well described, there are few data concerning biological predictive factors of response to HDM in myeloma patients. Dasgupta et al. 3 showed the impact of a polymorphism of glutathione S-transferase P1 (GSTP1) Ile105Val in 222 patients randomized to receive standard-dose or HDM. Schilthuizen et al. 4 investigated the role of single nucleotide polymorphisms (SNPs) in genes encoding the drug-metabolizing enzymes CYP3A4, CYP3A5, ABCB1 (multidrug resistance 1, MDR1), GSTM1 and GSTT1 in 209 newly diagnosed MM patients included in a clinical trial. These authors compared single with double intensive therapy and observed no significant association between polymorphisms and outcome either after treatment with induction chemotherapy or after high-dose therapy. Vangsted et al. 5 analyzed polymorphisms in the DNA repair genes ERCC1, ERCC2 and XRCC3, and in the apoptotic genes PPP1R13L and CD3EAP in 348 patients with MM undergoing autologous BMT. Carriers of the combination of variant alleles of ERCC2 K751Q and XRCC3 T241M had 2.8-fold longer time to treatment failure (P ¼ 0.0002).
These data suggest that genes involved in drug metabolism and DNA repair influence response to therapy and outcome in patients receiving HDM for MM. Given the likelihood that response and toxicity to therapy are multifactorial, we performed a study with the aim to detect possible associations between candidate polymorphisms and clinical parameters related with MM. Thus, we analyzed 209 SNPs in 95 genes involved in drug metabolism, DNA repair, apoptosis and cell-cycle regulation in a series of 169 patients receiving vincristine, doxorubicin (adriamycin), and dexamethasone (VAD) induction therapy followed by HDM for MM.
Materials and methods

Patient samples
Peripheral blood samples were obtained from patients with MM for whom the treatment regimen included one or two courses of HDM (140 or 200 mg/m 2 ) with SCT. Patients were accrued in Lyon (107 from the Hospices Civils de Lyon, France) and in Edmonton (62 from the Cross Cancer Center, Edmonton, Canada), after having obtained written informed consent. The protocol was approved by the ethical committees of both institutions. Samples were drawn at various time points, including at diagnosis or during follow-up. For patients accrued after high-dose therapy, samples were obtained at least 6 months after HDM had been administered. OS and freedom from progression (FFP) time were available for all the patients enrolled into the study. All patients (169) received VAD induction therapy and at least one course of HDM (minimum dose of 140 mg/m 2 ) and 58 patients received a second course (median total dose of 340 mg/m 2 for both courses). Twelve patients received an allograft after a first course of HDM. Patient and treatment characteristics are presented in Table 1 . Mucositis data were available only for patients collected in Lyon.
DNA genotyping
Peripheral blood cells were purified by Ficoll-Hypaque as previously described. 6 Genomic DNA was extracted from blood samples with the use of a QIAamp 96 DNA Blood kit (Qiagen, Hilden, Germany), or with Puregene chemistry (Gentra Systems, Minneapolis, MN, USA) on an Autopure instrument (Gentra Systems). Samples that yielded an insufficient amount of DNA at extraction were subjected to whole-genome amplification by use of a phi29-based protocol (GenomiPhi; Amersham Biosciences, Uppsala, Sweden) or reextracted by Puregene chemistry. DNA concentrations were measured by using PicoGreen doublestranded DNA quantification kits (Molecular Probes, Leiden, the Netherlands). All polymorphisms were analyzed simultaneously for each sample by a microarray technique based on the arrayed primer extension (APEX) principle. We used an extension of a microarray designed previously called 'Metabochip', implemented with more polymorphisms, as reported below. 7, 8 APEX consists of a sequencing reaction primed by an oligonucleotide anchored with its 5 0 end to a glass slide and terminating just one nucleotide before the polymorphic site. A DNA polymerase extends the oligonucleotide by adding one fluorescently labeled dideoxy-nucleotide complementary to the variant base. Reading the incorporated fluorescence identifies the base in the target sequence. Because both sense and antisense strands are probed, two oligonucleotides were designed for each polymorphism. The flanking sequences and their related APEX oligonucleotides have been described previously. 7 APEX gives a very high concordance when compared to the standard genotyping or sequencing methods.
The polymorphisms were selected on the basis of the following criteria: (1) having a biological significance demonstrated through functional studies, (2) being associated with biological end points in previous epidemiological studies, (3) having been previously associated with clinical outcome in MM. 3, 5, 9 However, for some DNA repair and cell-cycle control genes there were no variants that met these criteria. Therefore, for some genes we added selected SNPs from dbSNP (http://www.ncbi.nlm.nih.gov/ SNP/) which either had a frequency of the rare allele higher that 0.25 (to allow the highest statistical power to detect associations), or coded for missense changes. Although the biological effect of many of the polymorphisms selected for study is not known, we expect that these criteria should have maximized the likelihood of having chosen SNPs with functional significance or associated with cancer. The list of polymorphisms and genes analyzed is given in Supplementary materials or available on request.
Genomic DNAs were amplified to enrich the fragments carrying the SNPs by using specific primer pairs. Primer and probe sequences and protocols for PCR, as well as the APEX protocols, have already been reported in previous papers. 7, 8 Statistical analysis Clinical outcome parameters included response to therapy, progression of disease and death from whatever cause. FFP was calculated as the time between response and the date to disease progression. OS was calculated as the time between initiation of therapy and time of death, for whatever cause (death due to myeloma, to complications or to unrelated scale. An ECOG grade of 3 or 4 was considered to correspond to highgrade mucositis. The correlation between polymorphisms and the occurrence of high-grade mucositis was performed using the Mann-Whitney U-test. All statistical analyses were performed using Statistica 6.0.
Results
In this retrospective study, the overall response rate (complete þ very good þ partial responses) among evaluable patients was 77% after induction therapy and 94% after HDM. High-grade mucositis was observed in 40/107 (37%) of evaluable patients. The median FFP was 45 months and the OS was 91 months. These values are greater than those usually observed in prospective series of patients receiving HDM for MM and can be explained by the retrospective nature of this analysis, as a number of patient samples were obtained after having received HDM.
Association between genotypes and response to therapy As shown in Table 2 , SNPs in ABCB1, BRCA1, CYP2E1, CYP3A4, ERCC5, NAT1, PARP and TP53BP2 were associated with response (defined as partial, very good or complete) to VAD therapy. Carriers of the variant allele of SNP rs2242480 (trivially named 20230G4A) within CYP3A4 had a response rate of 54.2% (grouping heterozygotes with rare homozygotes) compared to 81.3% for the common homozygotes. For the other genes, the differences in response rates between genotypic groups ranged between 11 and 33%.
Response to HDM (defined as complete or very good response) was significantly associated with polymorphisms within genes ALDH2, BRCA1, CYP1A1, CYP1B1, CYP2E1, ERCC1, ERCC4, GSTP1, GSTT2, NAT1, NBS1, XRCC1 and XRCC2 (Table 3 ). The differences in response rates among genotypic subgroups were in the order of 20-30% in this cohort. For example, when considering the polymorphism in the XRCC2 gene, rs718282, the response rate ranged between 25% (95% CI, 1-47) in patients with genotype CT and 55% (95% CI, 46-63) in patients with genotype CC (P ¼ 0.01).
Association between genotypes and patient outcome SNPs within CYP1A1, CYP1B1, CYP2C9, CYP2E1, MYH, OGG1, PARP, PCNA, RAD51, TPMT and XPC were found to be associated with the occurrence of disease progression in this patient population (Table 4 ). The impact of these polymorphisms on FFP was evaluated by comparing FFP survival curves using the log-rank test. Four polymorphisms were found to be significantly associated with FFP: CYP1A1 I462V with median FFP values of 907 days for the common AA genotype (homozygotes for I462) and 589 days for the AG (carriers of the Val 462) (P ¼ 0.01); PARP G1280R with median FFP values of 835 for GG1280 homozygotes and 924 days for the carriers of R1280 (P ¼ 0.02); CYP2E1 rs641343 with a median FFP values of 882 days for the TT genotypes and 977 days for the TA genotypes (P ¼ 0.02) and RAD51 rs1801320, with a median FFP values of 1082 days for the GG genotype and 520 days for the GC genotypes (P ¼ 0.04). When these four polymorphisms were included in a multivariate Cox analysis, three were found to be independently correlated with progression-free survival: CYP1A1 (P ¼ 0.0003), RAD51 (P ¼ 0.03) and PARP (P ¼ 0.02).
Moreover, SNPs within ALDH2, BARD1, BRCA1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, ERCC1, GSTA4, MYH, PCNA and TP53BP1 were found to be associated with death (Table 5 ). The impact of these polymorphisms on OS was evaluated by comparing OS curves using the log-rank test. SNPs within four genes were found to be significantly associated with OS: ALDH2 rs886205 (genotype AA vs other) with median values of OS of 3628 and 2572 days, respectively (P ¼ 0.01); BRCA1 P871L (TT vs CT) with median values of OS of 2385 days and 3012 days, respectively (P ¼ 0.05); CYP1A1 I462V (AA vs GA) with median values of OS of 3624 and 1750 days, respectively (P ¼ 0.0009) and MYH Q335H (GG vs others) with median OS values of 3619 and 2544 days, respectively (P ¼ 0.01). When these four polymorphisms were included in a multivariate Cox analysis, two were found to be independently correlated with OS: ALDH2 (P ¼ 0.04) and CYP1A1 (P ¼ 0.05).
Association between genotypes and chemotherapy-induced mucositis Polymorphisms in BRCA1, CDKN1A and XRCC1 were associated with severe mucositis (Table 6 ). The differences in incidence of high-grade mucositis were found to be clinically significant, with 9% in patients with the GA genotype in BRCA1 rs4986850 GA genotype (95% CI, 0-33) and 41% in patients with the GG genotype (95% CI, 30-50).
Discussion
The biology of MM has made giant strides in the past few years and these have been correlated both with the definition of biomarkers of prognostic subgroups and with significant therapeutic advances. 10 Cytogenetic studies have shown, on large series, that chromosome 13 alterations are associated with worse outcome. 11, 12 More recently, it has been suggested that translocations involving chromosome 14, such as t(4;14), defined a poor prognostic group. 13 There are still few reports regarding polymorphisms in MM, although this body of data is steadily growing.
Our results suggest that several genes involved in drug metabolism and the maintenance of genome stability are potentially associated with response to therapy and outcome in myeloma patients receiving VAD induction followed by HDM. The use of microarray-based genotyping techniques allows investigators to examine large numbers of polymorphisms, thereby providing biomarkers potentially useful for defining prognostic subgroups. Conversely, multiple testing inherent in a many-marker association study of this kind can lead to false-positive results. When the P-values of our study were adjusted with Bonferroni's correction, none of the statistical association holds. For this reason our results should be taken with caution. This should be particularly true when there is an inconsistent trend with the allele dosage, for example, when the two types of homozygotes have similar responses and the heterozygotes are different (for example, P871L within BRCA1 and response to HDM). However, it should be stressed that Bonferroni's correction is considered an overly stringent method of adjustment, and it has been proposed that it could be avoided when the study has an exploratory nature.
14 Another limitation is the small number of patients in some of the genotypic subgroups, requiring confirmation in control series.
VAD induction therapy: role of polymorphisms within ABCB1 and GSTP1 The genetic variant 2677T within ABCB1 codes for the amino-acid change serine-to-alanine at codon 892 within ABCB1. This variant was found to be associated with an increased response to VAD, and this was related to the allele dosage (66.7, 77.8 and 89.7% of responses in GG, GT and TT genotypes, respectively). Polymorphisms in ABCB1 coding for the MDR1 gene have been previously reported to be associated with response to VAD, a finding that may be explained by the fact that vincristine and doxorubicin are both substrates for the P-glycoprotein efflux pump. 15, 16 The presence of the 2677T variant has been related to higher plasma levels of numerous drugs. [17] [18] [19] In this study we also observed associations previously described for GSTP1 (A114V) and response to VAD. Thus, our data reinforce the findings of previous works showing that variant GSTP1 is associated with therapy outcome in HDM therapy for MM. 3, 4, 9 The valine allele has been shown to have a possible functional effect on GSTP1 enzyme activity by decreasing enzymatic activity and detoxification capacity. 20 GSTP1 binds to reduced glutathione and is involved in the detoxification of reactive oxygen species, which consequently maintains cellular redox balance. 21 Alterations in GSTP1 may be involved in oxidative stress and apoptosis. In addition, GSTP1 has a pivotal role in the regulation of stress kinases, such as MAP, p38, ERK and JNK/stress-activated protein kinase, kinases that are involved in the intracellular signal transduction pathways against stress. 22, 23 Response to high-dose melphalan: role of the polymorphism D693N within BRCA1 Heterozygotes Asn/Asp at codon 693 within BRCA1 had a higher response rate to HDM (77.3%) than common homozygotes (Asp/Asp) (45.2%). Melphalan is one of the most widely used and effective DNA cross-linker drugs. It has been shown that enhanced interstrand cross-link (ICL) repair through the Fanconi anemia FA/BRCA pathway contributes to acquired drug resistance in melphalan-resistant myeloma cell lines, and disruption of this pathway reverses drug resistance. 24 NBS1, which was weakly associated with response to HDM in our study, also belongs to this pathway. These results suggest that polymorphisms within the FA/BRCA pathway could be important in the response to the ICL induced by melphalan.
It should be noted also that the heterozygotes for BRCA1 D693N have also had a lower incidence of highgrade mucositis than common homozygotes (9.1 vs 41.3%, respectively). More generally, DNA repair genes are prime candidates to determine whether a cancer cell is sensitive to melphalan. In keeping with the observation by Vangsted et al. 5 who observed correlations between polymorphisms in ERCC2 and XRCC3 and outcome, we observed that polymorphisms of ERCC1, ERCC4, XRCC1 and XRCC2 were correlated with response to HDM. These data confirm the major role of genes involved in DNA repair in the determination of sensitivity to melphalan.
FFP: role of the polymorphism R939Q within XPC The role of XPC in tumor progression has already been reported in other settings. It has been shown that deficiencies in XPC are important both in the progression of bladder tumors and in the resistance to cisplatin of various cancer cell lines. 25 It has also been suggested that the polymorphism R939Q could affect the function of the gene. In fact, a significant correlation was found between Lys939Gln genotypes and DNA damage following treatment of cell lines with benzo(a)pyrene-diol-epoxide or by g-radiation.
26 Table 4 Polymorphisms associated with FFP in patients with MM receiving HDM 
Melphalan-induced mucositis
Toxicity remains a major limitation in the treatment of patients with HDM, precluding this type of therapeutic strategy in elderly patients. Van Ness et al. 27 showed that diarrhea was associated with genotypes of TGF-b, CYP3A4 and ERCC2 after HDM, whereas IL-6 polymorphisms were significantly associated with infection. Sonneveld et al.
28
reported that patients homozygous for the CYP3A5 minor allele had increased toxicity (P ¼ 0.04), improved OS (P ¼ 0.01) and longer progression-free survival (P ¼ 0.04). In this study we found that polymorphisms in XRCC1 and BRCA1, genes involved in DNA repair, CDKN1A, a gene involved in cell proliferation, and CYP2C isoforms were associated with the occurrence of severe mucositis after HDM. In summary, our data and those of the literature support the hypothesis that polymorphisms of various genes involved in drug metabolism could be useful predictive factors to tailor therapy in patients with MM. The issue is complex due to the multifactorial nature of drug metabolism, antitumor effect and toxicity. Confirmatory prospective studies as well as functional approaches linking specific haplotypes to relevant phenotypes will be required to validate these polymorphisms as clinically useful markers. 25 
